Head-to-head · WeighScore
Ageless vs FMmeds
The verdict
Ageless takes it — 84.8/100 to 63.2/100.
Ageless grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the broadest compounded storefronts on the board — GLP-1, NAD+, sermorelin, TRT and more under one roof, in both injectable and oral routes, on low headline pricing (semaglutide $119/mo, tirzepatide $169/mo) — offset by a compounded-only catalog and an undisclosed state list.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ageless | FMmeds |
|---|---|---|
| WeighScore | 84.8/100 | 63.2/100 |
| Grade | B | C |
| Scorecard rank | #10 | #260 |
| Semaglutide | $119/mo | $225/mo (all doses, compounded) |
| Tirzepatide | $169/mo | $265/mo (all doses, compounded) |
| Coverage | Varies by state | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #10 · B
Strengths
- Unusually broad compounded menu — GLP-1, NAD+, sermorelin, TRT, LDN and more, in both injectable and oral formats
- Low headline GLP-1 pricing — semaglutide $119/mo, tirzepatide $169/mo — no insurance, with Klarna/Affirm financing
- Fully online: licensed-clinician review and discreet delivery, with upfront compounded/not-FDA disclosures
- Oral routes available (drops and troches), not injection-only
Where it loses points
- Everything is compounded and not FDA-approved — not equivalent to brand Wegovy/Ozempic/Zepbound
- Oral GLP-1 drops and troches lack robust absorption/efficacy evidence versus injectables
- No published state-availability list and no named legal entity or medical group
- Thin public track record, and advertised prices are floors set after clinical review
Graded #260 · C
Strengths
- All 50 states plus DC covered, stated in the Terms
- Operating LLC and full Manhattan Beach, CA address disclosed
- Named 503A pharmacy partner (Manifest Pharmacy, Greer SC)
- Aggressive 12-month pricing — semaglutide $95/mo and tirzepatide $145/mo, at the low end of the market
- Flat pricing across all dose strengths — no dose-escalation surcharge
Where it loses points
- Compounded only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
- Publishes the FDA compounded-medication disclaimer (medication is not FDA-approved)
- Clinical network not separately named
- LegitScript Certified, but the specific ID isn't shown
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.